Recent Company News

• 02:23 PM ET May 12, 2026
  

  Transcript Intelligence: argenx at Bank of America Securities Healthcare Conference ($817.50, +4.22)

• 05:03 PM ET May 07, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:40 AM ET May 08, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:27 PM ET May 08, 2026
  

  argenx announces US FDA approval expanding VYVGART and VYVGART Hytrulo for use in all adult patients living with generalized myasthenia gravis ($782.17, 0.00)

• 02:35 PM ET May 08, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 10-May

• 10:50 AM ET May 07, 2026
  

  Transcript Intelligence: argenx Q1 Earnings Guidance ($787.25, -20.30)

• 10:50 AM ET May 07, 2026
  

  Transcript Intelligence: argenx Q1 Earnings Themes ($787.12, -20.43)

• 10:50 AM ET May 07, 2026
  

  Transcript Intelligence: argenx Q1 Earnings Q&A ($787.12, -20.43)